» Articles » PMID: 31679074

Prognostic Significance of KN Motif and Ankyrin Repeat Domains 1 (KANK1) in Invasive Breast Cancer

Overview
Specialty Oncology
Date 2019 Nov 4
PMID 31679074
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: KN motif and ankyrin repeat domains 1 (KANK1) plays an important role in cytoskeleton maintenance and contributes to the regulation of cell proliferation, adhesion and apoptosis. KANK1 is involved in progression of a variety of solid tumours; however, its role in invasive breast cancer (BC) remains unknown. This study aims to evaluate the clinicopathological and prognostic value of KANK1 expression in operable BC.

Methods: KANK1 expression was assessed at the transcriptomic level using multiple BC cohorts; the Molecular Taxonomy of BC International Consortium cohort (METABRIC; n = 1980), The Cancer Genome Atlas BC cohort (TCGA; n = 949) and the publicly available BC transcriptomic data hosted by BC Gene-Expression Miner (bc-GenExMiner v4.0) and Kaplan-Meier plotter?. The Nottingham BC cohort (n = 1500) prepared as tissue microarrays was used to assess KANK1 protein expression using immunohistochemistry (IHC). The association between clinicopathological variables and patient outcome was investigated.

Results: In the METABRIC cohort, high expression of KANK1 mRNA was associated with characteristics of good prognosis including lower grade, absence of lymphovascular invasion and HER2 negativity (all; p < 0.001) and with better outcome [p = 0.006, Hazards ratio, (HR) 0.70, 95% CI 0.54-0.91]. High KANK1 protein expression was correlated with smaller tumour size and HER2 negativity, and better outcome in terms of longer breast cancer-specific survival [p = 0.013, HR 0.7, 95% CI 0.536-0.893] and time to distant metastasis [p = 0.033, HR 0.65, 95% CI 0.51-0.819].

Conclusion: These results supported that upregulation of KANK1 works as a tumour suppressor gene in BC and is associated with improved patients' outcomes.

Citing Articles

KANK1 promotes breast cancer development by compromising Scribble-mediated Hippo activation.

Guo S, Liu Z, Wang G, Sun Z, Yu K, Fawcett J Nat Commun. 2024; 15(1):10381.

PMID: 39613731 PMC: 11607453. DOI: 10.1038/s41467-024-54645-9.


The role of the ALKBH5 RNA demethylase in invasive breast cancer.

Woodcock C, Alsaleem M, Toss M, Lothion-Roy J, Harris A, Jeyapalan J Discov Oncol. 2024; 15(1):343.

PMID: 39127986 PMC: 11317455. DOI: 10.1007/s12672-024-01205-8.


α-Hederin Saponin Augments the Chemopreventive Effect of Cisplatin against Ehrlich Tumors and Bioinformatic Approach Identifying the Role of SDF1/CXCR4/p-AKT-1/NFκB Signaling.

Elaidy S, El-Kherbetawy M, Abed S, Alattar A, Alshaman R, Eladl M Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986504 PMC: 10056433. DOI: 10.3390/ph16030405.


Draft Genome Sequence of the Earthworm .

Arumugaperumal A, Sudalaimani D, Arumugaswami V, Sivasubramaniam S Curr Genomics. 2023; 23(2):118-125.

PMID: 36778974 PMC: 9878837. DOI: 10.2174/1389202923666220401095626.


Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer.

Kariri Y, Joseph C, Alsaleem M, Elsharawy K, Alsaeed S, Toss M Cancers (Basel). 2022; 14(22).

PMID: 36428736 PMC: 9688237. DOI: 10.3390/cancers14225643.


References
1.
Craze M, El-Ansari R, Aleskandarany M, Cheng K, Alfarsi L, Masisi B . Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Res Treat. 2018; 174(1):79-91. DOI: 10.1007/s10549-018-5060-z. View

2.
Clark E, Golub T, Lander E, Hynes R . Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000; 406(6795):532-5. DOI: 10.1038/35020106. View

3.
Murata T, Arii S, Nakamura T, Mori A, Kaido T, Furuyama H . Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol. 2001; 35(4):474-81. DOI: 10.1016/s0168-8278(01)00169-6. View

4.
Gyorffy B, Lanczky A, Eklund A, Denkert C, Budczies J, Li Q . An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2009; 123(3):725-31. DOI: 10.1007/s10549-009-0674-9. View

5.
Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View